Annual CFO
-$53.29 M
-$19.83 M-59.25%
December 31, 2023
Summary
- As of February 8, 2025, ANTX annual cash flow from operations is -$53.29 million, with the most recent change of -$19.83 million (-59.25%) on December 31, 2023.
- During the last 3 years, ANTX annual CFO has fallen by -$47.92 million (-893.44%).
- ANTX annual CFO is now -893.44% below its all-time high of -$5.36 million, reached on December 31, 2020.
Performance
ANTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$12.01 M
+$2.38 M+16.53%
September 30, 2024
Summary
- As of February 8, 2025, ANTX quarterly cash flow from operations is -$12.01 million, with the most recent change of +$2.38 million (+16.53%) on September 30, 2024.
- Over the past year, ANTX quarterly CFO has increased by +$5.59 million (+31.75%).
- ANTX quarterly CFO is now -678.16% below its all-time high of -$1.54 million, reached on March 31, 2021.
Performance
ANTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$61.05 M
-$207.00 K-0.34%
September 30, 2024
Summary
- As of February 8, 2025, ANTX TTM cash flow from operations is -$61.05 million, with the most recent change of -$207.00 thousand (-0.34%) on September 30, 2024.
- Over the past year, ANTX TTM CFO has dropped by -$1.77 million (-2.98%).
- ANTX TTM CFO is now -3856.71% below its all-time high of -$1.54 million, reached on March 31, 2021.
Performance
ANTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ANTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -59.3% | +31.8% | -3.0% |
| 3 y3 years | -893.4% | +31.8% | -3.0% |
| 5 y5 years | -893.4% | +31.8% | -3.0% |
ANTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -160.1% | at low | -78.1% | +31.8% | -198.1% | at low |
| 5 y | 5-year | -893.4% | at low | -678.2% | +31.8% | -3856.7% | at low |
| alltime | all time | -893.4% | at low | -678.2% | +31.8% | -3856.7% | at low |
AN2 Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.01 M(-16.5%) | -$61.05 M(+0.3%) |
| Jun 2024 | - | -$14.38 M(-18.2%) | -$60.84 M(+2.6%) |
| Mar 2024 | - | -$17.59 M(+3.1%) | -$59.28 M(+11.3%) |
| Dec 2023 | -$53.29 M(+59.2%) | -$17.07 M(+44.6%) | -$53.29 M(+21.5%) |
| Sep 2023 | - | -$11.80 M(-8.0%) | -$43.86 M(+5.6%) |
| Jun 2023 | - | -$12.82 M(+10.6%) | -$41.55 M(+8.4%) |
| Mar 2023 | - | -$11.60 M(+51.8%) | -$38.32 M(+14.5%) |
| Dec 2022 | -$33.46 M | -$7.64 M(-19.5%) | -$33.46 M(-3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$9.49 M(-1.1%) | -$34.82 M(+16.0%) |
| Jun 2022 | - | -$9.60 M(+42.3%) | -$30.02 M(+16.9%) |
| Mar 2022 | - | -$6.74 M(-25.0%) | -$25.68 M(+25.4%) |
| Dec 2021 | -$20.48 M(+281.9%) | - | - |
| Dec 2021 | - | -$8.99 M(+91.7%) | -$20.48 M(+78.3%) |
| Sep 2021 | - | -$4.69 M(-10.8%) | -$11.49 M(+69.0%) |
| Jun 2021 | - | -$5.26 M(+240.7%) | -$6.80 M(+340.7%) |
| Mar 2021 | - | -$1.54 M | -$1.54 M |
| Dec 2020 | -$5.36 M | - | - |
FAQ
- What is AN2 Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for AN2 Therapeutics?
- What is AN2 Therapeutics annual CFO year-on-year change?
- What is AN2 Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for AN2 Therapeutics?
- What is AN2 Therapeutics quarterly CFO year-on-year change?
- What is AN2 Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for AN2 Therapeutics?
- What is AN2 Therapeutics TTM CFO year-on-year change?
What is AN2 Therapeutics annual cash flow from operations?
The current annual CFO of ANTX is -$53.29 M
What is the all time high annual CFO for AN2 Therapeutics?
AN2 Therapeutics all-time high annual cash flow from operations is -$5.36 M
What is AN2 Therapeutics annual CFO year-on-year change?
Over the past year, ANTX annual cash flow from operations has changed by -$19.83 M (-59.25%)
What is AN2 Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ANTX is -$12.01 M
What is the all time high quarterly CFO for AN2 Therapeutics?
AN2 Therapeutics all-time high quarterly cash flow from operations is -$1.54 M
What is AN2 Therapeutics quarterly CFO year-on-year change?
Over the past year, ANTX quarterly cash flow from operations has changed by +$5.59 M (+31.75%)
What is AN2 Therapeutics TTM cash flow from operations?
The current TTM CFO of ANTX is -$61.05 M
What is the all time high TTM CFO for AN2 Therapeutics?
AN2 Therapeutics all-time high TTM cash flow from operations is -$1.54 M
What is AN2 Therapeutics TTM CFO year-on-year change?
Over the past year, ANTX TTM cash flow from operations has changed by -$1.77 M (-2.98%)